Ruxolitinib — Drug Intelligence | 41 EU Trials

Filter these 41 trials by condition, phase, country and more.

Open in Search →

41 Registered trials

20 Recruiting

19 Completed trials

24 Sponsors

20 Countries

Phase III

Phase II

Phase I/II

Phase III: 14 Phase II/III: 2 Phase II: 19 Phase I/II: 4 Phase IV: 1 Phase I (Other): 1

Oversight events:

4 urgent safety measures across 4 trials

View oversight register →

Indications tested

Myelofibrosis 10 Primary myelofibrosis 3 Chronic graft versus host disease 3 Acute graft versus host disease 2 Vitiligo 2 Chronic graft versus host disease in skin 1 Myeloproliferative neoplasm 1 Acute myeloid leukaemia 1 Chronic graft versus host disease in liver 1 Acute graft versus host disease in skin 1 Myelodysplastic syndrome 1 Thrombocytopenia 1

Sponsors using this IMP

Incyte Corp. 12 Assistance Publique Hopitaux De Paris 3 AbbVie Deutschland GmbH & Co. KG 2 Kartos Therapeutics Inc. 2 Karyopharm Therapeutics Inc. 2 Ryvu Therapeutics S.A. 2 Bristol-Myers Squibb Services Unlimited Company 1 Celgene Corp. 1 iOnctura SA 1 Janssen - Cilag International 1 Medac Gesellschaft fuer klinische Spezialprapaerate mbH 1 Medical Center - University Of Freiburg 1

All trials

41 total

Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Newly Diagnosed Patients with Polycythemia Vera. A Danish Safety and Efficacy… Pending

2024-518216-39-00 Phase II 1 country Region Sjaelland
A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t… Pending

2025-523555-66-00 Phase III 9 countries Novartis Pharma AG
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. Recruiting

2025-522052-13-00 Phase II/III 9 countries Ospedale Pediatrico Bambino Gesu
RVU120 Rollover Study Recruiting

2025-521673-14-00 Phase II 4 countries Ryvu Therapeutics S.A.
Clinical study of ruxolitinib and venetoclax for children with relapsed or refractory leukemia or lymphoma with mutations in the IL-7R/JAK-S… Recruiting

2022-501867-42-01 Phase I/II 11 countries Princess Maxima Center For Pediatric Oncology
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsacl… Recruiting

2022-501687-18-00 Phase II 8 countries Incyte Corp.
A Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Children and Adoles… Recruiting

2024-518156-24-00 Phase III 7 countries Incyte Corp.
Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS1) Recruiting

2024-517632-22-00 Phase III 6 countries Incyte Corp.
Study of Ruxolitinib Cream in Participants with Hidradenitis Suppurativa (TRuE-HS2) Recruiting

2024-517633-40-00 Phase III 7 countries Incyte Corp.
A study to evaluate the efficacy and safety of ruxolitinib cream in children (6 to <12 years old) with non-segmental vitiligo Recruiting

2024-513171-41-00 Phase III 12 countries Incyte Corp.
Blocage de l'interféron-ɣ par le ruxolitinib pour le traitement de la myosite à inclusion : un essai de phase IIb Recruiting

2023-507666-32-00 Phase II 1 country Assistance Publique Hopitaux De Paris
A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting

2024-515252-20-00 Phase I/II 2 countries iOnctura SA
Phase 2 Trial to determine the safety and efficacy of simultaneous treatment with ruxolitinib and extracorporeal photopheresis for patients … Recruiting

2023-507754-33-00 Phase II 2 countries Medical Center - University Of Freiburg
A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha … Recruiting

2024-516109-21-00 Phase III 1 country The University Of Birmingham
Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with … Recruiting

2024-518316-39-00 Phase II/III 1 country Medical University Of Lodz
R-HLH Recruiting

2024-516105-23-01 Phase II 1 country Assistance Publique Hopitaux De Paris
Ruxolitinib rollover study Recruiting

2023-507225-42-00 Phase II 1 country Incyte Corp.
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis Recruiting

2023-504724-25-00 Phase III 13 countries Kartos Therapeutics Inc.
Clinical trial testing an investigational drug RVU120 for myelofibrosis (myeloproliferative neoplasm, MPN) Recruiting

2024-511688-27-00 Phase II 2 countries Ryvu Therapeutics S.A.
JAKAHDI - JAK inhibitors in acquired hemophagocytic syndrome in the ICU Recruiting

2023-504513-77-00 Phase II 1 country Assistance Publique Hopitaux De Paris
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate… Recruiting

2024-511309-47-00 Phase II 13 countries Karyopharm Therapeutics Inc.
Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Recruiting

2023-504865-21-00 Phase III 10 countries Merck Sharp & Dohme LLC
INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru… Ended

2022-502168-19-00 Phase II 4 countries Incyte Corp.
Randomized open-label Phase 2 trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adver… Ended

2023-505863-35-00 Phase II 3 countries Janssen - Cilag International

Showing 1–24 of 41 trials

← All drugs A–Z